Nuvectis Pharma reports Q3 net loss $5.9M; provides NXP800/NXP900 clinical updates

Nuvectis Pharma, Inc.

2022-Q3 EPS reported -$1.03

Net loss $5.9M for Q3 2022 vs $4.7M in Q3 2021; cash $23.6M as of Sep 30, 2022.
Phase 1a dose escalation of NXP800 ongoing; Phase 1b expansion expected to start Q1 2023.
IND-enabling studies for NXP900 ongoing; IND or equivalent submission expected Q1 2023.
Positive preclinical data for NXP800 in ARID1a-mutated gastric cancer model.
Cash runway into H2 2024; formed Scientific Advisory Board.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Nuvectis Pharma, Inc. reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 8, 2022, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the third quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Nuvectis Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-115724

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.